About Synairgen plc
Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: LON
- Symbol: SNG
- Previous Close: $0.34
- 50 Day Moving Average: $19.17
- 200 Day Moving Average: $23.15
- 52-Week Range: GBX 12.10 - GBX 38
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Market Cap: $25.12M
- Outstanding Shares: 91,340,000
Consensus Ratings for Synairgen plc (LON:SNG) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 91.50|
Analysts' Ratings History for Synairgen plc (LON:SNG)
(Data available from 2/20/2015 forward)
|11/29/2016||FinnCap||Reiterated Rating||Corporate||GBX 137|
|9/22/2016||N+1 Singer||Lower Price Target||Buy||GBX 47 -> GBX 46|
Earnings History for Synairgen plc (LON:SNG)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Synairgen plc (LON:SNG)
Current Year EPS Consensus Estimate: $-4.12 EPS
Dividend History for Synairgen plc (LON:SNG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Synairgen plc (LON:SNG)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/11/2015||Shaw,Simon J B||Insider||Buy||65,217||GBX 23||£14,999.91|
Latest Headlines for Synairgen plc (LON:SNG)
What is Synairgen plc's stock symbol?
Synairgen plc trades on the London Stock Exchange (LON) under the ticker symbol "SNG."
Where is Synairgen plc's stock going? Where will Synairgen plc's stock price be in 2017?
1 brokers have issued 1 year price objectives for Synairgen plc's shares. Their predictions range from GBX 46 to GBX 137. On average, they expect Synairgen plc's stock price to reach GBX 91.50 in the next twelve months.
When will Synairgen plc announce their earnings?
Synairgen plc is scheduled to release their next quarterly earnings announcement on Monday, March, 20th 2017.
How do I buy Synairgen plc stock?
Shares of Synairgen plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of Synairgen plc stock cost?
One share of Synairgen plc stock can currently be purchased for approximately GBX 27.50.